Filing Details

Accession Number:
0001225208-22-006816
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-10 20:54:42
Reporting Period:
2022-05-07
Accepted Time:
2022-05-10 20:54:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1099800 Edwards Lifesciences Corp EW Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 364316614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1196661 Jr E Donald Bobo One Edwards Way
Irvine CA 92614
Cvp,Strategy/Corp Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-05-07 604 $100.52 59,316 No 4 F Direct
Common Stock Acquisiton 2022-05-08 12,600 $0.00 71,916 No 4 M Direct
Common Stock Disposition 2022-05-08 7,612 $100.52 64,304 No 4 F Direct
Common Stock Acquisiton 2022-05-09 6,725 $35.20 71,029 No 4 M Direct
Common Stock Disposition 2022-05-09 6,725 $98.71 64,304 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Rights Disposition 2022-05-08 12,600 $0.00 12,600 $0.00
Common Stock Employee Stock Option (Right to Acquire) Disposition 2022-05-09 6,725 $0.00 6,725 $35.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-05-08 2026-05-07 No 4 M Direct
73,975 2017-05-12 2023-05-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 38,268 Indirect 401(k)
Common Stock 117,320 Indirect By Trust
Footnotes
  1. On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
  2. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022.